As filed with the Securities and Exchange Commission on March 29, 201
9
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
_____________________________________
Aclaris Therapeutics, Inc.
(Exact name of Registrant as specified in its charter)
|
|
|
Delaware
|
|
46-0571712
|
(State or other jurisdiction of Incorporation or organization)
|
|
(I.R.S. Employer Identification No.)
|
640 Lee Road, Suite 200
Wayne, PA 19087
_____________________________________
(Address of principal executive offices) (Zip code)
2015 Equity Incentive Plan
_____________________________________
(Full title of the plan)
Neal Walker
President and Chief Executive Officer
Aclaris Therapeutics, Inc.
640 Lee Road, Suite 200
Wayne, PA 19087
(484) 324-7933
_____________________________________
(Name and address of agent for service) (Telephone number, including area code, of agent for service)
Copies to:
|
|
Brian F. Leaf
Brent B. Siler
Mark Ballantyne
Cooley LLP
11951 Freedom Drive
Reston, VA 20190-5640
(703) 456-8000
|
Kamil Ali-Jackson
Chief Legal Officer
Aclaris Therapeutics, Inc.
640 Lee Road, Suite 200
Wayne, PA 19087
(484) 324-7933
|
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
|
Large accelerated filer
|
|
☐
|
|
|
Accelerated filer
|
|
☒
|
Non-accelerated filer
|
|
☐
|
|
|
Smaller reporting company
|
|
☒
|
|
|
|
|
|
Emerging growth company
|
|
☒
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
☒
POWER OF ATTORNEY
Know All Persons By These Presents
, that each person whose signature appears below constitutes and appoints Neal Walker, Kamil Ali-Jackson and Frank Ruffo, and each or any one of them, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
|
|
|
Signature
|
Title
|
Date
|
|
|
|
/s/ Neal Walker
Neal Walker
|
President, Chief Executive Officer and Director
(Principal Executive Officer)
|
March 29, 2019
|
|
|
|
/s/ Frank Ruffo
Frank Ruffo
|
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)
|
March 29, 2019
|
|
|
|
/s/ Stephen A. Tullman
Stephen A. Tullman
|
Chairman of the Board of Directors
|
March 29, 2019
|
|
|
|
/s/ Christopher Molineaux
Christopher Molineaux
|
Director
|
March 29, 2019
|
|
|
|
/s/ Anand Mehra, M.D.
Anand Mehra, M.D.
|
Director
|
March 29, 2019
|
|
|
|
/s/ William Humphries
William Humphries
|
Director
|
March 29, 2019
|
|
|
|
/s/ Andrew Powell
Andrew Powell
|
Director
|
March 29, 2019
|
|
|
|
/s/ Andrew Schiff
|
Director
|
March 29, 2019
|
Andrew Schiff
|
|
|
|
|
|
/s/ Bryan Reasons
|
Director
|
March 29, 2019
|
Bryan Reasons
|
|
|